HC Wainwright Has Optimistic Outlook of MIST FY2026 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Equities researchers at HC Wainwright boosted their FY2026 earnings per share estimates for Milestone Pharmaceuticals in a research report issued on Monday, December 15th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($0.70) per share for the year, up from their previous forecast of ($0.71). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2027 earnings at ($0.61) EPS, FY2028 earnings at $0.53 EPS and FY2029 earnings at $1.03 EPS.

Several other analysts have also weighed in on MIST. Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Cowen upgraded Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday. TD Cowen raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price target for the company in a report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday. Finally, Wells Fargo & Company increased their target price on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a report on Tuesday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.00.

Milestone Pharmaceuticals Trading Down 2.3%

Shares of MIST stock opened at $2.15 on Wednesday. The company has a market capitalization of $183.12 million, a P/E ratio of -2.62 and a beta of 0.41. Milestone Pharmaceuticals has a 12-month low of $0.63 and a 12-month high of $3.06. The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 2.74. The firm has a 50-day moving average price of $2.19 and a 200 day moving average price of $1.92.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its earnings results on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.05.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Propel Bio Management LLC raised its position in shares of Milestone Pharmaceuticals by 186.1% during the third quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock worth $10,250,000 after acquiring an additional 3,333,333 shares during the last quarter. Orbimed Advisors LLC acquired a new stake in Milestone Pharmaceuticals in the third quarter worth about $6,444,000. Simplify Asset Management Inc. raised its holdings in Milestone Pharmaceuticals by 186.2% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after purchasing an additional 1,842,974 shares during the last quarter. Pathstone Holdings LLC bought a new stake in Milestone Pharmaceuticals during the 3rd quarter worth about $2,000,000. Finally, Boxer Capital Management LLC acquired a new position in Milestone Pharmaceuticals during the 3rd quarter valued at about $1,333,000. 86.18% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.